Cisco Systems Inc. (CSCO) Pops 10.51% for February 11

Equities Staff  |

One of the S&P 500’s big winners for Thursday February 11 was Cisco Systems Inc. (CSCO) as the company’s stock climbed 10.51% to $24.88 on volume of 78.08 million shares.

The stock opened at $24.09 and saw an intraday low of $24.09 and an intraday high of $24.96. All told, the day saw a per-share gain of $2.365. The stock’s average daily volume of 29.6 million and 5.08 billion shares outstanding. Cisco Systems Inc. now has a 50-day SMA is $25.29 and 200-day SMA is $26.86, and it has a 52-week high of $30.31 and a 52-week low of $22.46.

Cisco Systems Inc is engaged in designing, manufacturing and selling of Internet Protocol (IP) based networking products and services related to the communications and information technology (IT) industry.

Based out of San Jose, CA, Cisco Systems Inc. has 70,000 employees and, after today’s trading, reached a market cap of $126.27 billion. Its P/S ratio is n/a, P/B ratio is 2.1, and P/FCF ratio is 22.5.

For a complete fundamental analysis analysis of Cisco Systems Inc., check out’s Stock Valuation Analysis report for CSCO. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Frank Ricotta CEO BurstIQ

Matt Bird sits down with Frank Ricotta, CEO BurstIQ, at the World Economic Forum at Davos 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.